Stay updated with breaking news from Revascularization Device. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Penumbra (NYSE:PEN – Get Free Report) had its price objective dropped by investment analysts at Citigroup from $390.00 to $320.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price objective indicates a potential upside of 35.08% from the company’s […]
Penumbra, Inc. (NYSE:PEN – Get Free Report) Director Don W. Kassing sold 444 shares of the stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $288.66, for a total value of $128,165.04. Following the transaction, the director now directly owns 1,458 shares of the company’s […]
Abbot Financial Management Inc. lowered its stake in Penumbra, Inc. (NYSE:PEN – Free Report) by 20.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 973 shares of the company’s stock after selling 246 shares during the period. Abbot Financial Management Inc.’s […]
FORA Capital LLC lowered its stake in shares of Penumbra, Inc. (NYSE:PEN – Free Report) by 2.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,602 shares of the company’s stock after selling 134 shares during the quarter. […]
Harvest Fund Management Co. Ltd increased its position in shares of Penumbra, Inc. (NYSE:PEN – Free Report) by 823.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 840 shares of the company’s stock after acquiring an additional 749 shares during the quarter. Harvest […]